DGAP-News: myoscience Announces $25 Million Series E Financing Round

myoscience 

12.09.2013 13:00
---------------------------------------------------------------------------

REDWOOD CITY, Calif., 2013-09-12 13:00 CEST (GLOBE NEWSWIRE) --
myoscience, inc., the makers of iovera*, is pleased to announce that it has
closed on $25 million in Series E financing. The funds for the Series E
financing came entirely from existing investors. The iovera* system uses
Focused Cold Therapy(TM) to treat peripheral nerve conditions for both cosmetic
and pain indications. 

'We are all excited about the results of iovera* for cosmetic use in the
European Union and Canada, and the growing potential of our product in the
treatment of focal pain in the United States,' says Clint Carnell, CEO of
myoscience. 'This financing demonstrates the high degree of commitment and
confidence that the investors have in the company's potential.' 

'We are ready and willing to support the future growth of myoscience, expanding
geography and indications to recognize the full potential of their platform
technology,' says Jan Pensaert of Valiance Asset Management Limited. 

The Series E financing included the following existing investors: Accuitive
Medical Ventures, American Equities Overseas, DeNovo Ventures, Medicis Capital,
Saratoga Ventures, and Valiance Asset Management Limited. 

About myoscience

Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy(TM),
the standard of care for the treatment of peripheral nerve conditions. Focused
Cold Therapy is currently approved in Europe and Canada for temporary wrinkle
reduction, temporary pain reduction and treatment of dermatologic conditions.
The myoscience technology has also been cleared in the United States for use in
pain management and general surgical use. For more information, please visit
www.myoscience.com. 

The myoscience logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13581 


         CONTACT: Alexandra Mack, myoscience inc.
         Tel: 00 1 650 421 0609
         amack@myoscience.com
News Source: NASDAQ OMX



12.09.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      myoscience
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US9902131674
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------